| NCT ID | NCT06974305 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-09-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-09-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functional magnetic resonance imaging \[fMRI\]) relate to abnormal interictal electrical activity associated with epilepsy (measured by electroencephalography \[EEG\]). The study will also compare how the three imaging modalities localize regions of abnormal function in the brain.
Eligibility Criteria
Inclusion Criteria: * Age 18 or older Additional Inclusion Criteria for Subjects with Epilepsy: * Diagnosed with epilepsy with abnormal interictal EEG Exclusion Criteria: * Contraindications to PET, MRI, or EEG imaging * History of severe brain disease such as stroke and head trauma * History of brain surgery * History of type I or II diabetes mellitus * Fasting plasma glucose level \>200 mg/dL * Employed under direct supervision of the PI conducting the research Additional Exclusion Criteria for Healthy Subjects: * Current use of drugs that modulate brain function * Current or past history of major medical, neurological, or psychiatric conditions
Contact & Investigator
Ciprian Catana, MD, PhD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06974305 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06974305 currently recruiting?
Yes, NCT06974305 is actively recruiting participants. Contact the research team at mallen27@mgh.harvard.edu for enrollment information.
Where is the NCT06974305 trial being conducted?
This trial is being conducted at Charlestown, United States.
Who is sponsoring the NCT06974305 clinical trial?
NCT06974305 is sponsored by Massachusetts General Hospital. The principal investigator is Ciprian Catana, MD, PhD at Massachusetts General Hospital. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.